^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PIGF inhibitor

    Related drugs:
    7d
    DEUTERON: A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P4, N=45, Recruiting, Bayer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    10d
    PRISM: 4D-150 in Patients with Neovascular (Wet) Age-Related Macular Degeneration (clinicaltrials.gov)
    P1/2, N=215, Recruiting, 4D Molecular Therapeutics | N=150 --> 215 | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2024 --> Nov 2025
    Enrollment change • Trial completion date • Trial primary completion date • Gene therapy
    |
    Eylea (aflibercept intravitreal)
    2ms
    Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) (clinicaltrials.gov)
    P3, N=413, Completed, Alvotech Swiss AG | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    2ms
    DME HOME: Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT (clinicaltrials.gov)
    P=N/A, N=308, Not yet recruiting, Zhongshan Ophthalmic Center, Sun Yat-sen University
    New trial
    |
    Eylea (aflibercept intravitreal)
    2ms
    DEUTERON: A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P4, N=45, Not yet recruiting, Bayer
    New P4 trial
    |
    Eylea (aflibercept intravitreal)
    2ms
    Comparison of the Efficacy of Conbercept and Aflibercept in Different Treatment Regimens for Exudative Age-related Macular Degeneration (ChiCTR2400087042)
    P4, N=140, Completed, The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University
    New P4 trial
    |
    Eylea (aflibercept intravitreal)
    2ms
    PULSAR: Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (clinicaltrials.gov)
    P3, N=1011, Completed, Bayer | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    3ms
    TELeMAC: Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1 (clinicaltrials.gov)
    P3, N=46, Recruiting, Centre Hospitalier Universitaire Dijon | Trial completion date: Jan 2025 --> Dec 2027 | Trial primary completion date: Jan 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    3ms
    ELARA: A Single-Arm Study of Aflibercept 8 mg Dosed in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) (clinicaltrials.gov)
    P3, N=400, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    4ms
    PHOTON: Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease (clinicaltrials.gov)
    P2/3, N=660, Completed, Regeneron Pharmaceuticals | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    4ms
    ELARA: A Single-Arm Study of Aflibercept 8 mg Dosed in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, Regeneron Pharmaceuticals
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    5ms
    Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) (clinicaltrials.gov)
    P3, N=35, Completed, Regeneron Pharmaceuticals | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    5ms
    PHOTONiC: A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P3, N=322, Recruiting, Bayer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    5ms
    PRECISION: Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema (clinicaltrials.gov)
    P4, N=23, Completed, The Cleveland Clinic | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    6ms
    Changes in Inflammatory Biomarkers Including Soluble CD14 and Hyperreflective Foci in DME Patients Treated With Aflibercept (FORESIGHT) (clinicaltrials.gov)
    P4, N=23, Completed, Hyewon Chung | Unknown status --> Completed | N=47 --> 23 | Trial completion date: Sep 2022 --> Feb 2024
    Trial completion • Enrollment change • Trial completion date
    |
    Eylea (aflibercept intravitreal)
    6ms
    Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) (clinicaltrials.gov)
    P3, N=413, Active, not recruiting, Alvotech Swiss AG | Trial completion date: Jan 2025 --> Oct 2024
    Trial completion date
    |
    Eylea (aflibercept intravitreal)
    6ms
    PHOTONiC: A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P3, N=322, Not yet recruiting, Bayer
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    6ms
    INTRAMED-CRVO: Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion (clinicaltrials.gov)
    P4, N=51, Completed, University of Athens
    New P4 trial
    |
    Eylea (aflibercept intravitreal)
    6ms
    Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E (clinicaltrials.gov)
    P4, N=30, Completed, The University of Hong Kong | Recruiting --> Completed | N=64 --> 30
    Trial completion • Enrollment change
    |
    Eylea (aflibercept intravitreal)
    6ms
    Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) (clinicaltrials.gov)
    P3, N=35, Active, not recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    6ms
    Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study (clinicaltrials.gov)
    P2, N=30, Completed, Moorfields Eye Hospital NHS Foundation Trust | Unknown status --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    7ms
    SPECTRUM-US: An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting (clinicaltrials.gov)
    P=N/A, N=800, Not yet recruiting, Regeneron Pharmaceuticals
    New trial • Real-world evidence • Real-world
    |
    Eylea (aflibercept intravitreal)
    7ms
    Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma (clinicaltrials.gov)
    P2, N=32, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Initiation date: Oct 2023 --> Feb 2024
    Trial initiation date • Metastases
    |
    Libtayo (cemiplimab-rwlc) • Zaltrap (ziv-aflibercept IV)
    7ms
    VISION-AF: A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema (clinicaltrials.gov)
    P4, N=100, Completed, Bayer | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    7ms
    Proteomic study of vitreous in proliferative diabetic retinopathy patients after treatment with aflibercept: a quantitative analysis based on 4D label-free technique. (PubMed, Int J Ophthalmol)
    Proteomic analysis is an approach of choice to explore the molecular mechanisms of PDR. Our data show that multiple proteins are differentially changed in PDR patients after intravitreal injection of aflibercept, among which C1QTNF5, CLU, TIMP1 and SIRPα may become targets for future treatment of PDR and resolution of anti-VEGF resistance.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • CLU (Clusterin) • SIRPA (Signal Regulatory Protein Alpha)
    7ms
    Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment (clinicaltrials.gov)
    P=N/A, N=60, Active, not recruiting, Singapore National Eye Centre | Recruiting --> Active, not recruiting | N=160 --> 60
    Enrollment closed • Enrollment change
    |
    Visudyne (verteporfin) • Eylea (aflibercept intravitreal)
    7ms
    One Year Trial Evaluating Safety of Ozurdex With Eylea (clinicaltrials.gov)
    P4, N=50, Completed, Texas Retina Associates | Unknown status --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    7ms
    FIREFLEYE next: Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090 (clinicaltrials.gov)
    P3, N=96, Active, not recruiting, Bayer | Trial completion date: Jul 2025 --> Oct 2025 | Trial primary completion date: Jul 2025 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    8ms
    ALVOEYE-D: Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease (clinicaltrials.gov)
    P3, N=35, Active, not recruiting, Alvotech Swiss AG | Recruiting --> Active, not recruiting
    Enrollment closed
    8ms
    Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity (clinicaltrials.gov)
    P4, N=12, Completed, Seoul National University Hospital
    New P4 trial
    |
    Eylea (aflibercept intravitreal)
    8ms
    Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment (clinicaltrials.gov)
    P4, N=17, Terminated, Wake Forest University Health Sciences | N=10 --> 17 | Trial completion date: Aug 2024 --> Dec 2023 | Suspended --> Terminated | Trial primary completion date: Jun 2024 --> Dec 2023; IRB stopped study due to safety concerns. No further data collection and what has been collected is not appropriate for analysis.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    VEGFA (Vascular endothelial growth factor A)
    |
    Eylea (aflibercept intravitreal)
    8ms
    An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK) (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Bayer
    New trial
    |
    Eylea (aflibercept intravitreal)
    8ms
    PULSOV: Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections (clinicaltrials.gov)
    P=N/A, N=60, Active, not recruiting, Fondation Ophtalmologique Adolphe de Rothschild | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    8ms
    Mean Visual Acuity Changes Following Five Injections of Aflibercept (clinicaltrials.gov)
    P=N/A, N=48, Active, not recruiting, McMaster University | Recruiting --> Active, not recruiting | Trial completion date: Jan 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Sep 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    8ms
    Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed by Intraoperative OCT (the VIDEO Study): Study Protocol for a Randomized Controlled Trial (clinicaltrials.gov)
    P4, N=64, Recruiting, Tianjin Medical University Eye Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    9ms
    ALVOEYE-D: Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease (clinicaltrials.gov)
    P3, N=35, Recruiting, Alvotech Swiss AG | Not yet recruiting --> Recruiting
    Enrollment open
    9ms
    Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors. (PubMed, Cancer Med)
    The combination of sapanisertib and ziv-aflibercept was generally tolerable and demonstrated anti-tumor activity in heavily pre-treated patients with advanced malignancies.
    P1 data • Journal • Combination therapy • Metastases
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV)
    9ms
    Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1, N=83, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Jan 2024
    Trial completion • Trial completion date • Combination therapy • Surgery • Metastases
    |
    sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV)
    9ms
    The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema (clinicaltrials.gov)
    P=N/A, N=2500, Recruiting, Bayer | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence • Real-world
    9ms
    ALVOEYE-D: Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease (clinicaltrials.gov)
    P3, N=35, Not yet recruiting, Alvotech Swiss AG | Initiation date: Nov 2023 --> Mar 2024 | Trial primary completion date: Feb 2024 --> May 2024
    Trial initiation date • Trial primary completion date
    9ms
    FAR-WEST: Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD. (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Nantes University Hospital
    New trial
    |
    Lucentis (ranibizumab)
    9ms
    PULSOV: Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Fondation Ophtalmologique Adolphe de Rothschild | Trial completion date: May 2024 --> Mar 2025 | Trial primary completion date: May 2024 --> Mar 2025
    Trial completion date • Trial primary completion date